Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EvoPAR-Prostate01
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- NCT06120491 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built an HCP commentary report on EvoPAR-Prostate01 (saruparib in metastatic castration-sensitive prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EvoPAR-Prostate01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Castration-Sensitive Prostate Cancer
- Interventions
- Saruparib; Placebo; Abiraterone Acetate; Darolutamide; Enzalutamide
- Arms
- Arm 1: Saruparib (AZD5305) + Physician's Choice NHA · Experimental
- Arm 2: Placebo + Physician's Choice NHA · Placebo comparator
- Enrollment
- 1,898
- Primary outcomes
- Radiographic Progression-Free Survival (rPFS)
- Sponsor
- AstraZeneca
- Start
- Nov 21, 2023
- Primary completion
- Sep 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06120491 · updated Jul 29, 2026
Publications
linked from the registry- Azad AA, Agarwal N, Armstrong AJ, Hellmis E, Sugimoto M, Urun Y, Xing N, Aregay M, Lima J, Meulendijks D, Chi KN. Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. Future Oncol. 2026 Apr;22(10):1153-1163. doi: 10.1080/14796694.2026.2655433. Epub 2026 Apr 14. PubMed 41979035